COVID-19 and Cardiovascular Diseases

• Published in: Advances in experimental medicine and biology Vol. 1318; p. 263
• Main Authors: Geraiely, Babak, Samiei, Niloufar, Sadeghipour, Parham, Talasaz, Azita H, Mortazavi, Seyedeh Hamideh, Sattarzadeh Badkoubeh, Roya
• Format: Journal Article
• Language: English
• Published: United States 01.01.2021
• Subjects: Cardiovascular Diseases - diagnosis; Cardiovascular Diseases - epidemiology; COVID-19; Humans; Pandemics; SARS-CoV-2; ST Elevation Myocardial Infarction; COVID-19; Cardiovascular disease; SARS-CoV-2; Outbreak
• ISSN: 0065-2598
• DOI: 10.1007/978-3-030-63761-3_16

We herein seek to expound on up-to-the-minute information regarding cardiovascular disease in the era of coronavirus disease 2019 (COVID-19) by highlighting acute myocardial injury caused by COVID-19 and probing into its pathophysiology, clinical signs, diagnostic tests, and treatment modalities. We aim to share the latest research findings vis-à-vis cardiovascular disease patients with confirmed or suspected COVID-19 on the association between hypertension and this infectious disease along with the relevant recommendations; describe the mechanism of coronary artery disease in such patients together with the necessary measures in the setting of non-ST-segment elevation acute coronary syndrome, ST-segment elevation myocardial infarction, and chronic coronary syndrome; discuss tachy- and bradyarrhythmias in the COVID-19 setting alongside their treatments; elucidate coagulopathies, venous thromboembolism, and its prophylactic measures in the context of this infection; set out the cardiopulmonary resuscitation protocol as well as the pertinent safety concerns during the current pandemic; and, finally, explicate drug-drug interactions between COVID-19 and cardiovascular medication in hypertension, acute coronary syndrome, heart failure, venous thromboembolism, and arrhythmias.